Evommune, Inc. (NYSE:EVMN – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the sixteen brokerages that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $30.80.
EVMN has been the topic of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Evommune in a research note on Friday, September 18th. William Blair cut Evommune from an “outperform” rating to a “market perform” rating in a report on Monday, June 29th. Stifel Nicolaus set a $30.00 price objective on Evommune in a research note on Wednesday, September 9th. Weiss Ratings downgraded Evommune from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 11th. Finally, Leerink Partners dropped their price objective on shares of Evommune from $28.00 to $22.00 and set an “outperform” rating for the company in a report on Wednesday, September 9th.
Check Out Our Latest Stock Analysis on EVMN
Evommune Stock Down 4.1%
EVMN stock opened at $5.16 on Thursday. Evommune has a 12 month low of $5.09 and a 12 month high of $33.20. The firm has a market cap of $187.33 million and a P/E ratio of -0.47. The company’s 50-day moving average price is $9.92 and its two-hundred day moving average price is $16.16.
Evommune (NYSE:EVMN – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.21). Equities analysts predict that Evommune will post -3.29 EPS for the current year.
Institutional Investors Weigh In On Evommune
A number of institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC bought a new stake in Evommune during the first quarter valued at $20,615,000. Defilade Capital Management L.P. grew its holdings in Evommune by 215.0% during the 1st quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company’s stock worth $15,601,000 after acquiring an additional 463,171 shares during the period. Velan Capital Investment Management LP raised its position in shares of Evommune by 1.1% in the 2nd quarter. Velan Capital Investment Management LP now owns 451,255 shares of the company’s stock worth $5,997,000 after acquiring an additional 5,000 shares in the last quarter. Perceptive Advisors LLC bought a new position in shares of Evommune in the 1st quarter worth about $10,308,000. Finally, Stempoint Capital LP raised its position in shares of Evommune by 184.1% in the 1st quarter. Stempoint Capital LP now owns 193,777 shares of the company’s stock worth $4,385,000 after acquiring an additional 125,581 shares in the last quarter.
About Evommune
Evommune, Inc is a clinical-stage biotechnology company focused on developing new treatments for immune-mediated inflammatory diseases. The company’s research is centered on identifying therapies that address the underlying biological mechanisms driving chronic inflammation rather than primarily treating symptoms.
Evommune is advancing a pipeline of investigational medicines designed for conditions with significant unmet medical needs, including dermatologic and other inflammatory disorders.
Featured Articles
- Five stocks we like better than Evommune
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for Evommune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evommune and related companies with MarketBeat.com's FREE daily email newsletter.
